RHBDF1 & RHBDF2 Knockout HEK293 Cell Line
Cat.No.:
EDC07972
Species:
Human
Cell Name:
HEK293
Gene:
RHBDF1 & RHBDF2
Gene ID:
64285 & 79651
Size:
1×10⁶cells
RHBDF1 & RHBDF2 Knockout HEK293 Cell Line is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performotion Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC07972 |
|---|---|
| Product Name | RHBDF1 & RHBDF2 Knockout HEK293 Cell Line |
| Species | Human |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene ID | |
| Gene | RHBDF1 & RHBDF2 |
| Associated Diseases | Non-tumor |
| Digestion Time | ~1 min |
| Morphology | Adherent |
| Passage Ratio | 1:3 |
| Complete Culture Medium | DMEM+10% FBS |
| Freezing Medium | 95% complete culture medium + 5% DMSO |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying RHBDF1 & RHBDF2 function, RHBDF1 & RHBDF2 Knockout HEK293 Cell Line or RHBDF1 & RHBDF2 overexpression HEK293 Cell Line?
The choice depends on whether you are studying combined iRhom function for ADAM17/TACE regulation or distinguishing iRhom-mediated shedding from iRhom-independent processes. The Double Knockout line is uniquely valuable for asking whether ADAM17 maturation and activity are required for these processes — combined iRhom1 + iRhom2 loss essentially eliminates ADAM17 function (ADAM17 fails to exit the ER without iRhom partners), producing an ADAM17 functional null without disrupting the ADAM17 gene itself. Single-iRhom rescue (iRhom1 alone or iRhom2 alone) in the double knockout enables paralog-specific functional studies.
For TACE/ADAM17 biology research, the EDITGENE RHBDF1 & RHBDF2 Double Knockout in HEK293 is the gold-standard genetic tool — it produces a functional ADAM17 null and enables clean single-paralog rescue. This product complements the parallel double knockout in A-549. Rescue with iRhom1 alone, iRhom2 alone, or both enables comprehensive paralog dissection — the design for distinguishing iRhom1-versus iRhom2-specific TACE substrate selection. Rescue with iRhom catalytically-dead variants tests whether maturation chaperone activity is sufficient.
What are the application scenarios for this model?
Primary applications:
• Functional ADAM17 null: combined iRhom1 + iRhom2 loss creates a clean ADAM17 functional null without disrupting the ADAM17 gene — useful for studies separating ADAM17-dependent from ADAM17-independent phenotypes.
• Single-iRhom rescue: re-introduction of iRhom1 alone or iRhom2 alone enables paralog-specific TACE substrate selection studies — the gold-standard experimental design.
• ADAM17 inhibitor mechanism: critical genetic control for testing TACE inhibitors and antibody-based ADAM17 blockers.
• Substrate selectivity: identification of iRhom1-versus iRhom2-preferred substrates through differential rescue analysis.
EDITGENE recommends this HEK293-based double knockout as the gold-standard genetic tool for paralog-specific iRhom-ADAM17 research; parallel A-549 double knockout complements for cancer applications.
Is this RHBDF1 & RHBDF2 Knockout HEK293 Cell Line compatible with overexpression rescue experiments?
Yes, and rescue experiments are uniquely powerful in this double knockout background:
• Single-iRhom rescue: re-introduction of iRhom1 alone or iRhom2 alone in the double knockout enables paralog-specific TACE substrate selection studies — the gold-standard experimental design.
• Combined rescue: simultaneous iRhom1 + iRhom2 re-expression restores ADAM17 maturation capacity and serves as the positive control.
• Construct design: codon-modified RHBDF1 or RHBDF2 sequences with small C-terminal tags (FLAG, HA). Both must preserve the rhomboid family pseudoenzyme architecture.
• Functional readout: rescue should restore ADAM17 Golgi maturation and substrate shedding; paralog-specific rescue reveals iRhom1-versus iRhom2-preferred substrates.
HEK293's very high transfection efficiency enables systematic paralog-specific rescue experiments.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download